Deputy Director in the Division of Behavioral and Social Research (DBSR)
Dr. Dana Jeffrey Plude is Deputy Director in the Division of Behavioral and Social Research (DBSR) where he also manages a research portfolio on cognitive aging (including experimental aging research, driving and memory/attention/decision-making). He also serves as the point-person for training/career development applications, conference grants and small business activities. Prior to joining NIA in December 2016, he served as Associate Director and Research/Review Integrity Officer in the Division of Receipt & Referral in the Center for Scientific Review (CSR) before which he was Chief of the Bio-behavioral and Behavioral Processes Integrated Review Group (BBBP IRG) and Scientific Review Officer for the Cognition and Perception study section as well as Special Emphasis Panels including those involving fellowships and small business applications. During his tenure at CSR he also served as Acting Division Director (AIDS, Behavioral and Populations Sciences), Acting NIH Research Integrity Officer and Acting Chief of the Population Sciences and Epidemiology IRG. He has won several NIH Director/CSR Director awards and has contributed to several NIH Regional Seminars. Before joining CSR in 2002, he was Associate Professor and Associate Chair in Psychology at the University of Maryland – College Park for 17 years. He earned a Ph.D. in Psychology from Syracuse University, where he specialized in lifespan development and mental function in the elderly. His basic and applied research centered on aging, selective attention and memory and this research was supported in part by funding from NIA, including pre-doctoral T32 support, a post-doctoral F32 NRSA award and R01 and SBIR funding.
NIH has a number of new initiatives focused on specific areas in neurology, including research in Alzheimer’s Disease, pain and opioid addition, as well as new technologies for researchers. Come hear about the Alzheimer’s Disease and AD-Related Dementias (AD/ADRD), Helping to End Addition Long-term (HEAL) Initiatives, and Brain Research through Advancing Innovative Neurotechnologies (BRAIN).